- Home
- MRVI vs ALLO Comparison
MRVI vs ALLO Comparison
Compare MRVI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRVI | ALLO |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.0M | 707.6M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MRVI | ALLO |
|---|---|---|
| Price | $5.21 | $2.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $4.13 | ★ $8.35 |
| AVG Volume (30 Days) | 2.6M | ★ 6.9M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.29 | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,743,000.00 | N/A |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $7.87 | $142,416.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.99 | $0.99 |
| 52 Week High | $5.32 | $4.46 |
Technical Indicators
Market Signals| Indicator | MRVI | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 67.64 | 48.86 |
| Support Level | $3.27 | $1.85 |
| Resistance Level | N/A | $2.36 |
| Average True Range (ATR) | 0.25 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 81.45 | 49.03 |
Price Performance
Historical ComparisonAbout MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).